drugset / Trial / NCT06232707
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Timeline
- Start
- 2024-05-03
- Primary completion
- 2025-11-16
- Completion
- 2030-09-21
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alnuctamab | Protein / enzyme biologic | — | — |
| Comparator | Carfilzomib | Other / unclassified | — | — |
| Comparator | Daratumumab | Monoclonal antibody | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |
| Comparator | Elotuzumab | Monoclonal antibody | — | — |
| Comparator | Pomalidomide | Other / unclassified | — | — |